AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01556425 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vivitrol
Description: Participants receiving this intervention will receive the FDA-approved dose, route, and schedule of administration of VIVITROL. The dose of VIVITROL of 380 mg will be delivered intramuscularly every 4 weeks.
Study NCT01556425 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Employment-based opiate abstinence reinforcement
Description: This intervention will require participants to provide opiate-negative urine samples on Monday, Wednesday and Friday to maintain their maximum pay. If a participant provides an opiate-positive urine sample, or fails to provide a scheduled sample, their base pay will be reset from $8 per hour to $1 per hour. On each day after the reset that the participant provides a urine sample that meets the opiate abstinence criteria and attends the workplace for at least 5 minutes, their base pay will increase by $1 per hour until it reaches the maximum of $8 per hour.
Study NCT01556425 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care Control
Description: Participants receiving this intervention will be invited to attend the workplace and outpatient drug abuse counseling.
Study NCT01783080 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Activation for return to work
Description: See Arm Description
Study NCT02774382 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin
Description: Already incl. in arm description
Study NCT02774382 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin
Description: Already incl. in arm description
Study NCT02774382 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplantation
Description: Already incl. in arm description
Study NCT02774382 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rectal bacteriotherapy
Description: Already incl. in arm description
Study NCT02845570 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 68Ga-DOTANOC PET/MRI
Study NCT02845570 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 18F-FDG PET/MRI
Study NCT01734577 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dry needling
Description: Sterile monofilament needles
Study NCT01734577 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham needling
Description: Applicator tubes from the sterile monofilament needles
Study NCT00691002 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcipotriol plus hydrocortisone (LEO 80190)
Description: Once daily application
Study NCT00691002 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LEO 80190 Vehicle
Study NCT00691002 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocortisone
Study NCT00691002 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcipotriol
Study NCT04618159 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: lactobacillus reuteri DSMZ 17648
Description: to evaluate if this product can eradicate helicobacter pylori
Study NCT01951820 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pliaglis
Description: Apply 0.2mg of compounded topical anesthetic (Pliaglis) to gums for 2.5 minutes before giving patient injection of local anesthetic.
Study NCT01951820 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Benzocaine
Description: Apply 0.2mg of topical anesthetic (benzocaine) to gums for 2.5 minutes before giving patient injection of local anesthetic.
Study NCT01951820 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Articaine
Description: Injection of 0.4mg of local anesthetic in gum tissue where topical anesthetic was placed
Study NCT01951820 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Articaine
Description: Injection of 0.4mg of local anesthetic in gum tissue where topical anesthetic was placed
Study NCT03609697 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: group-based lifestyle intervention
Description: Involve education about pre-diabetes self-management, weight loss, behavioural modification skills, nutrition and physical activity.
Study NCT03609697 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Minimal intervention (SMS intervention)
Description: Text message related to general information about T2DM, pre-diabetes, and lifestyle modification.
Study NCT01888029 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation
Study NCT01888029 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: sham stimulation
Study NCT01445821 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Peripheral Blood Stem Cells
Description: Mobilized leukapheresis product
Study NCT01445821 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Peripheral Blood Stem Cells
Description: Mobilized leukapheresis product
Study NCT01445821 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: An alkylating agent which causes prevention of cell division by forming adducts with DNA
Study NCT01445821 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: An alkylating agent which causes prevention of cell division by forming adducts with DNA
Study NCT01445821 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesna
Description: Medication used to decrease the risk of hemorrhagic cystitis prophylaxis
Study NCT01445821 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mesna
Description: Medication used to decrease the risk of hemorrhagic cystitis prophylaxis
Study NCT01445821 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rATG
Description: A predominantly lymphocyte-specific immunosuppressive agent which contains antibodies specific to the antigens commonly found on the surface of T cells
Study NCT01445821 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rATG
Description: A predominantly lymphocyte-specific immunosuppressive agent which contains antibodies specific to the antigens commonly found on the surface of T cells
Study NCT01445821 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Steroid
Study NCT01445821 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone
Description: Steroid
Study NCT01445821 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Granulocyte-colony stimulating factor (G-CSF); a glycoprotein that stimulates the bone marrow to produce granulocytes and stem cells and release them into the bloodstream
Study NCT01445821 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Filgrastim
Description: Granulocyte-colony stimulating factor (G-CSF); a glycoprotein that stimulates the bone marrow to produce granulocytes and stem cells and release them into the bloodstream
Study NCT01445821 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Purine analog which inhibits DNA synthesis or repair
Study NCT01627899 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: One Touch VerioIQ Blood Glucose Monitor
Description: BGM with pattern alert technology and with associated pattern guide
Study NCT04344938 — intervention group
Intervention type: OTHER
Intervention: questionnair about Emerging Legal and Ehical Disputes Over Patient Confidentiality
Description: Many critical ethical questions arise in pandemic covid 19planning, preparedness and response. These include: Who will get priority access to medications, vaccines and intensive care unit beds, given the potential shortage of these essential resources? In the face of a pandemic, what obligations do health-care workers have to work notwithstanding risks to their own health and the health of their families? How can surveillance, isolation, quarantine and social-distancing measures be undertaken in a way that respects ethical norms? What obligations do countries have to one another with respect to pandemic covid 19 planning and response efforts?
Study NCT04588779 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Graston
Description: Ultrasound for 10 mins/1 set/ (3 sessions/week), Graston for 5 mins/1 set/ (3 sessions/week), Piriformis stretching exercises/ 10 reps with 30 sec hold/ 1 set/(3 sessions/week), Hip abductor strengthening/10 reps/1 set/(3 weeks), Hip extensor strengthening/10 reps/1 set/(3 weeks),~A total of 9 sessions for 3 weeks (3 sessions/week) were given each consisting of 20 mins.
Study NCT04588779 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual myofascial release
Description: Ultrasound for 10 mins/1 set/ (3 sessions/week), Manual myofascial release for 5 mins/1 set/ (3 sessions/week), Piriformis stretching exercises/ 10 reps with 30 sec hold/ 1 set/(3 sessions/week), Hip abductor strengthening/10 reps/1 set/(3 weeks), Hip extensor strengthening/10 reps/1 set/(3 weeks),~A total of 9 sessions for 3 weeks (3 sessions/week) were given each consisting of 20 mins.
Study NCT04486950 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-951
Description: TAK-951 intravenous infusion.
Study NCT04486950 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-951 Placebo
Description: TAK-951 placebo-matching intravenous infusion.
Study NCT01624662 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone propionate
Description: Delivered via Optinose Exhalation Delivery System
Study NCT01624662 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fluticasone propionate
Description: Delivered via Optinose Exhalation Delivery System
Study NCT03814070 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fiber-reinforced framework
Description: Glass fiber- reinforced framework is to be picked up over the implant abutments to strengthen the full arch acrylic restorations
Study NCT03814070 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: No framework
Description: Non-reinforced acrylic full arch prosthesis is to be picked up directly over the implant abutments.
Study NCT00361270 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hyp-8
Description: 8 weekly 1-hour sessions of therapist-guided hypnosis
Study NCT00361270 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hyp-2 w recordings
Description: 2 weeks of 1-hour sessions of therapist-guided hypnosis + 6 weeks of daily home practice with hypnosis CDs
Study NCT00361270 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hyp-8 w recordings
Description: 8 weekly 1-hour sessions of therapist-guided hypnosis + daily home practice with hypnosis CDs
Study NCT00361270 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: BIO
Description: 8 weekly 1-hour sessions of EMG Biofeedback without hypnotic suggestion
Study NCT02952274 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: mandibular overdenture retained with single midline implant using locator attachment
Study NCT02952274 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: mandibular overdenture retained with single midline implant using ball attachment
Study NCT02821715 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active comparator: Modafinil + placebo
Study NCT02821715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THN102 300/3
Study NCT02821715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THN102 300/27
Study NCT00137111 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Prednisone, Dexamethasone, Vincristine, Daunorubicin
Description: See Detailed Description sections for details on treatment interventions.
Study NCT00137111 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Doxorubicin, L-asparaginase, PEG-L-asparaginase, Erwinia asparaginase
Description: See Detailed Description sections for details on treatment interventions.
Study NCT00137111 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Methotrexate, Cyclophosphamide, Cytarabine, Etoposide
Description: See Detailed Description sections for details on treatment interventions.
Study NCT00137111 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Mercaptopurine, Imatinib
Description: See Detailed Description sections for details on treatment interventions.
Study NCT00137111 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: chemotherapy, intrathecal chemotherapy
Description: See Detailed Description sections for details on treatment interventions.
Study NCT00137111 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: steroid therapy, hematopoietic stem cell transplantation
Description: See Detailed Description sections for details on treatment interventions.
Study NCT04577235 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: severity of lung involvement with COVID-19.
Description: transthoracic lung ultrasound and throcic CT
Study NCT02721680 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Internal Awareness Training Program
Study NCT02721680 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: External Awareness Training Program
Study NCT00610987 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cefazolin
Description: Both groups will receive 1 gram (g) of IV cefazolin prior to incision, per standard protocol at our institution. A 2-g dose of cefazolin will be administered IV for patients weighing more than 80 kg. A second 1-g dose of cefazolin will be given three hours later if the patient is still in the operating room. Upon completion of the surgical procedure, Group I will receive 1-g doses of cefazolin every eight hours for the next 24 hours.
Study NCT00610987 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will be randomly assigned to one of two groups. Both groups will receive 1 gram (g) of IV cefazolin prior to incision, per standard protocol at our institution. A 2-g dose of cefazolin will be administered IV for patients weighing more than 80 kg. A second 1-g dose of cefazolin will be given three hours later if the patient is still in the operating room. Upon completion of the surgical procedure, Group II will receive no additional antibiotic. Instead, they will receive normal saline injection every eight hours as a placebo.
Study NCT01714687 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: balloon sinus dilation
Study NCT01714687 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: medical therapy
Study NCT00784654 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate (LDX)
Description: LDX 30, 50, or 70mg capsule once per day (open-label and double-blind periods)
Study NCT00784654 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule once per day (double-blind period)
Study NCT02989064 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Autologous genetically modified MAGE A10ᶜ⁷⁹⁶T cells
Description: Infusion of autologous genetically modified MAGE A10ᶜ⁷⁹⁶T on Day 1
Study NCT03448250 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Optimune
Description: Optimune is a web-based psychological intervention developed for women with breast cancer.
Study NCT03448250 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Care-As-Usual
Description: Participants are free to continue to engage with any treatment they require (i.e., CAU).
Study NCT00827021 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erythropoiesis Stimulating Agents (ESAs): epoetin alfa, beta or any other epoetin in equivalent dose.
Description: 4000 IU/week I.V. Until the end of the trial
Study NCT00827021 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Erythropoiesis Stimulating Agents (ESAs): epoetin alfa, beta or any other epoetin in equivalent dose.
Description: 18000 IU/week I.V. Until the end of the trial
Study NCT01187953 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prograf (tacrolimus)
Description: Administered per current product labeling
Study NCT01187953 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCP-Tacro
Description: Tacrolimus, once-per-day The initial dose of 0.17 mg/kg will be administered orally in the morning (before noon) within 24 hours following transplantation. Subsequent doses will be adjusted according to whole blood tacrolimus trough levels.
Study NCT02572752 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nintedanib
Description: 1 soft gelatine capsule, single dose, oral
Study NCT02572752 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nintedanib
Description: Nintedanib, 2 soft gelatine capsules, single dose, oral
Study NCT02572752 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nintedanib
Study NCT03143140 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PAFA
Description: percutaneous ablation of tumor feeding artery
Study NCT03143140 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: tumor ablation
Description: ablation of tumor area directly
Study NCT03143140 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: tumor ablation
Description: ablation of tumor area directly
Study NCT02302482 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The Lawton Instrumental Activities of Daily Living score (IADL), and the disability assessment of dementia score (DAD-6
Study NCT04676997 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: 200mg on days1,15 of Cycles 1-4 (Q2W); IV infusion. 200mg on day 1 of Cycles 5-8 (Q2W); IV infusion.
Study NCT04676997 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab paclitaxel
Description: 125 mg/m² on day 1, 8 and 15 of Cycles 1-4 (QW 3/4); IV infusion.
Study NCT04676997 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: 90 mg/m² on day 1 of Cycles 5-8 (Q2W); IV infusion.
Study NCT04676997 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 600 mg/m² on day 1 of Cycles 5-8 (Q2W); IV infusion.
Study NCT02930512 — intervention group
Intervention type: PROCEDURE
Intervention: DXA scan
Study NCT02930512 — intervention group
Intervention type: PROCEDURE
Intervention: pQCT scan
Study NCT04479995 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Horizon Program
Description: Telehealth videoconferencing sessions and questionnaires.
Study NCT04479995 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: Standard medical visits with additional paper or electronic booklet.
Study NCT03619382 — intervention group
Intervention type: RADIATION
Intervention: Cone Beam Computed Tomography
Description: Computer tomography (CT) of the foot/ankle for determination of motion and morphology
Study NCT03619382 — intervention group
Intervention type: RADIATION
Intervention: Radiographs
Description: Standard radiographs of the foot/ankle as part of the screening criteria
Study NCT03861559 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mometasone furoate nasal spray
Description: intranasal administration
Study NCT03861559 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo nasal spray
Description: intranasal administration
Study NCT01659008 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol
Study NCT01659008 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lysteda
Study NCT03440814 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DCCR
Description: Once daily oral administration
Study NCT03440814 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for DCCR
Description: Once daily oral administration
Study NCT00879697 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Walking Training
Description: The Walking Training program was performed using a treadmill. In each session, patients performed fifteen 2-min bouts of exercise followed by a 2-min rest interval, as previously described. Walking speed was set in order to induce perceived exertion of 11 to 13 and claudication pain in the last 30 seconds of each exercise bout.
Study NCT00879697 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Strength Training
Description: The strength training program consisted of 8 exercises (leg press, crunches, unilateral knee extension, seated row, unilateral knee flexion, seated bench press, calf raises on leg press, and seated back extension). In each exercise, subjects performed 3 sets of 10 repetitions with a 2-min interval between sets and exercises.
Study NCT05040594 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PavéDerm J-Fill Soft Dermal Filler
Description: Sodium Hyaluronate 20 mg with Lidocaine hydrochloride 3 mg/mL
Study NCT05040594 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Restylane® Lyft Lidocaine
Description: Sodium Hyaluronate 20 mg with Lidocaine hydrochloride 3 mg/mL
Study NCT01217021 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F] MNI-558
Description: Subjects will be injected with 5mCi, not to exceed >10% of 5mCI, of \[18F\]MNI-558, followed by PET imaging.
Study NCT04155671 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: POF
Description: Paclitaxel plus Oxaliplatin plus Leucovorin plus 5-FU
Study NCT04155671 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX plus PAC(ip)
Description: FOLFOX plus intraperitoneally paclitaxel